(redirected from antiviral resistance)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to antiviral resistance: Resistance to antiviral drugs


An effective upper bound on prices achieved because of many willing sellers at that price level.

Resistance Level

In technical analysis, a price that a security does not, or only rarely, rise above. Technical analysts identify a resistance level by looking at past performance. When the security approaches the resistance level, it is seen as an indication to sell the security, which will increase the supply, causing the security's price to fall back below the resistance level. If there are too many buyers, however, the security rises above the resistance level. When this occurs, the price of the security will likely continue to rise until it finds another resistance level. It is also called the overhead resistance level. See also: Price ceiling, Support (Support level).


An increased supply of a security. Compare support.


Resistance, or resistance level, is the top of a stock's current trading range, and the point at which the price is higher than investors are willing to pay. As stockholders sell at resistance level, the stock price goes down because supply exceeds demand.

For example, if, on a repeated basis, as stock A's price reaches $60, stockholders begin to sell, then $60 is considered its resistance level. But a trading range isn't fixed and investor attitudes change, so the resistance level tends to move higher or lower over time.

If stock A rises to $63 without a surge of selling, the current resistance line has been breached. This may be the result of a rising market or a bullish assessment of the stock's value. On the other hand, if selling increases at $57, that may become the new resistance level.

Conversely, the level at which demand exceeds supply and investors typically buy a certain stock is called support. It's the point that's considered the bottom of a stock's current trading range.

Technical analysts use the concepts of resistance and support in anticipating future stock price movements.

References in periodicals archive ?
Fry for the US Antiviral Resistance Surveillance Working Group [1]
Most patients infected with oseltamivir-resistant pandemic (H1N1) 2009 viruses were hospitalized (81%), had a severe immunocompromising condition (76%), and had been exposed to oseltamivir before collection of the specimen tested for antiviral resistance (89%) (Table); 9 (30%) had received oseltamivir as chemoprophylaxis, and 21 (70%) had received oseltamivir as treatment.
CDC will continue to conduct surveillance for antiviral resistance among influenza viruses throughout the upcoming season.
His research interests are vaccine development, antiviral resistance, and immunologic properties of influenza viruses.
Since October 1, 2010, a total of 364 influenza virus isolates have been tested for antiviral resistance.
Although the recently detected oseltamivir-resistant pandemic (H1N1) 2009 virus in Hong Kong was not a reassortant virus (4,5), we will continue to closely monitor antiviral drug resistance among circulating viruses, including pandemic (H1N1) 2009 virus and seasonal influenza virus A (H1N1), as well as influenza A (H3N2) viruses, to track how antiviral resistance evolves.
Since October 1, a total of 104 influenza viruses have been tested for antiviral resistance.
Indiscriminant administration of these agents could support proliferation of antiviral resistance in pandemic (H1N1) 2009 virus or an evolved variant.
Three additional cases of oseltamivir resistance among 2009 H1N1 viruses have been identified by other laboratories where antiviral resistance testing also is performed; thus, a total of 42 oseltamivir-resistant 2009 H1N1 viruses have been reported to CDC since September 1, 2009.